Edition:
United States

People: AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,081.00GBp
5:17am EDT
Change (% chg)

-71.00 (-1.38%)
Prev Close
5,152.00
Open
5,147.00
Day's High
5,154.00
Day's Low
5,081.00
Volume
347,938
Avg. Vol
2,343,847
52-wk High
5,585.07
52-wk Low
3,996.00

Mallon, Mark 

Mr. Mark Mallon is Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West of AstraZeneca PLC., since January 2013 and is responsible for the growth and performance of AstraZeneca’s commercial businesses in various regions, including Asia Pacific, Russia, Latin America, the Middle East and Africa. Since joining AstraZeneca in 1994, Mark has held multiple senior sales and marketing roles, including Regional Vice-President for Asia Pacific, President of AstraZeneca’s Chinese and Italian subsidiaries, Chief Operating Officer of AstraZeneca’s Japanese subsidiary and VicePresident of AstraZeneca’s US gastrointestinal and respiratory businesses. He has served as a member of the Board of Directors for Christiana Care, the largest hospital system in Delaware, and an Executive Committee Member for R&D-based Pharmaceutical Association Committee, the China industry association for innovative pharmaceutical companies. Mark began his career in the pharmaceutical industry in management consulting. He holds a degree in chemical engineering from the University of Pennsylvania and an MBA in marketing and finance from the Wharton School of Business.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Leif Johansson

611,000

Pascal Soriot

13,389,000

Marc Dunoyer

4,450,000

Fiona Cicconi

--

Sean Bohen

--

Pam Cheng

--
As Of  30 Dec 2016